Memphasys (ASX:MEM) has secured CE Mark approval for its Felix automated sperm selection system under the EU Medical Device Regulation, clearing the way for immediate commercial sales across Europe and other CE-recognised markets and marking a key inflection point in the company’s global growth strategy.
The approval unlocks access to an estimated €29+ million annual addressable market, with binding multi-year commercial agreements now activated, including a five-year European supply deal with CFA Italia valued at a minimum of ~$925,000 and a five-year exclusive Middle East and North Africa agreement with International Technical Legacy with minimum contracted purchases of $390,000.
Early cartridge orders placed ahead of contractual triggers indicate emerging clinic-level demand, while operational preparations by Memphasys and its partners position clinics for immediate utilisation.